Cutaneous Vasculitis Induced by Osimertinib-Reference-Cited by-同舟云学术

Cutaneous Vasculitis Induced by Osimertinib

Published:2019-12 Issue:12 Volume:14 Page:2188-2189
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hamada Kazuki,Oishi Keiji^ORCID,Okita Tomoko,Chikumoto Ayumi,Ohteru Yuichi,Murakawa Keita,Matsuda Kazuki,Uehara Sho,Suetake Ryo,Yamaji Yoshikazu,Murata Yoriyuki,Asami-Noyama Maki,Edakuni Nobutaka,Hirano Tsunahiko,Shimomura Yutaka,Matsunaga Kazuto

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer;Soria;N Engl J Med,2018

2. Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation;Ko;J Clin Oncol,2011

3. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib;Boeck;Ann Oncol,2007

4. Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: a case report;Su;Oncol Lett,2012

5. Skin involvement in cutaneous and systemic vasculitis;Marzano;Autoimmun Rev,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bilateral Hemorrhagic Occlusive Retinal Vasculitis Induced by Osimertinib in a Patient with Non-Small Cell Lung Cancer;Ocular Immunology and Inflammation;2024-08-08

2. Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature;JTO Clinical and Research Reports;2022-11

3. Cutaneous leukocytoclastic vasculitis of the leg, ulcerations, and subungual splinter hemorrhages: rare adverse reactions caused by cabozantinib treatment;Italian Journal of Dermatology and Venereology;2022-10

4. A rare case of erythema dyschromicum perstans arising in the setting of a third-generation tyrosine kinase inhibitor;Acta Oncologica;2022-06-06

5. Cutaneous leucocytoclastic vasculitis secondary to cabozantinib therapy for renal cell carcinoma;Clinical and Experimental Dermatology;2021-01-10